Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.
作者信息
Green A R, Mitchell B D, Tordoff A F, Youdim M B
出版信息
Br J Pharmacol. 1977 Jul;60(3):343-9. doi: 10.1111/j.1476-5381.1977.tb07506.x.
Abstract
摘要
相似文献
1
Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine.
Br J Pharmacol. 1977 Jul;60(3):343-9. doi: 10.1111/j.1476-5381.1977.tb07506.x.
2
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.
Br J Pharmacol. 1975 Nov;55(3):415-22. doi: 10.1111/j.1476-5381.1975.tb06946.x.
3
Preferential deamination of dopamine by an A type monoamine oxidase in rat brain.
Naunyn Schmiedebergs Arch Pharmacol. 1976;292(1):9-14. doi: 10.1007/BF00506483.
4
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.
J Neurochem. 1971 Jun;18(6):1053-66. doi: 10.1111/j.1471-4159.1971.tb12034.x.
5
Species differences in the deamination of dopamine and other substrates for monoamine oxidase in brain.
Psychopharmacology (Berl). 1980;72(1):27-33. doi: 10.1007/BF00433804.
6
A and B forms of monoamine oxidase within the monoaminergic neurons of the rat brain.
J Neurochem. 1986 Aug;47(2):569-76. doi: 10.1111/j.1471-4159.1986.tb04537.x.
7
Deamination of norepinephrine, dopamine, and serotonin by type A monoamine oxidase in discrete regions of the rat brain and inhibition by RS-8359.
Jpn J Pharmacol. 1991 Jan;55(1):121-8. doi: 10.1254/jjp.55.121.
8
The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions.
Naunyn Schmiedebergs Arch Pharmacol. 1983 Apr;322(3):198-202. doi: 10.1007/BF00500765.
9
Responses of developing rats to L-tryptophan plus an MAOI-I. Monitoring changes in behaviour, brain 5-HT and tryptophan.
Neuropharmacology. 1980 Apr;19(4):325-35. doi: 10.1016/0028-3908(80)90183-5.
10
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour.
Neuropharmacology. 1976 Mar;15(3):173-9. doi: 10.1016/0028-3908(76)90026-5.
引用本文的文献
1
Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations.
J Neural Transm (Vienna). 2023 Jun;130(6):847-861. doi: 10.1007/s00702-023-02623-8. Epub 2023 Mar 24.
2
Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate.
Int J Mol Sci. 2023 Feb 6;24(4):3201. doi: 10.3390/ijms24043201.
3
Revisiting the Role of Astrocytic MAOB in Parkinson's Disease.
Int J Mol Sci. 2022 Apr 18;23(8):4453. doi: 10.3390/ijms23084453.
4
A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.
J Neural Transm (Vienna). 2022 Jun;129(5-6):723-736. doi: 10.1007/s00702-022-02465-w. Epub 2022 Feb 2.
5
On the practical aspects of characterising monoamine oxidase inhibition in vitro.
J Neural Transm (Vienna). 2018 Nov;125(11):1685-1705. doi: 10.1007/s00702-018-1943-8. Epub 2018 Oct 29.
6
Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
J Neural Transm (Vienna). 2018 Nov;125(11):1719-1733. doi: 10.1007/s00702-018-1942-9. Epub 2018 Oct 19.
7
90 years of monoamine oxidase: some progress and some confusion.
J Neural Transm (Vienna). 2018 Nov;125(11):1519-1551. doi: 10.1007/s00702-018-1881-5. Epub 2018 Apr 10.
8
Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
J Neural Transm (Vienna). 2016 Feb;123(2):91-106. doi: 10.1007/s00702-014-1362-4. Epub 2015 Jan 22.
9
Molecular targets of the multifunctional iron-chelating drug, M30, in the brains of mouse models of type 2 diabetes mellitus.
Br J Pharmacol. 2014 Dec;171(24):5636-49. doi: 10.1111/bph.12862.
10
Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity.
J Neural Transm (Vienna). 2014 Apr;121(4):379-83. doi: 10.1007/s00702-013-1120-z. Epub 2013 Nov 23.
本文引用的文献
1
Protein measurement with the Folin phenol reagent.
J Biol Chem. 1951 Nov;193(1):265-75.
2
A SENSITIVE METHOD FOR SPECTROPHOTOFLUOROMETRIC ASSAY OF CATECHOLAMINES.
Int J Neuropharmacol. 1964 Dec;3:643-9. doi: 10.1016/0028-3908(64)90089-9.
3
Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain.
Br J Pharmacol. 1970 Jul;39(3):653-5. doi: 10.1111/j.1476-5381.1970.tb10373.x.
4
L-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice.
Science. 1970 May 15;168(3933):847-50.
5
The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines.
J Pharmacol Exp Ther. 1974 Jun;189(3):733-40.
6
Human brain monoamine oxidase: multiple forms and selective inhibitors.
Nature. 1972 Mar 31;236(5344):225-8. doi: 10.1038/236225b0.
7
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats.
Neuropharmacology. 1974 Nov;13(10-11):949-59. doi: 10.1016/0028-3908(74)90086-0.
8
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan.
J Neurochem. 1971 Jun;18(6):1053-66. doi: 10.1111/j.1471-4159.1971.tb12034.x.
9
Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranylcypromine plus L-DOPA.
Br J Pharmacol. 1976 May;57(1):141-7. doi: 10.1111/j.1476-5381.1976.tb07664.x.
10
Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration.
Br J Pharmacol. 1975 Nov;55(3):415-22. doi: 10.1111/j.1476-5381.1975.tb06946.x.
Zotero 插件